Assessment of new technologies: surrogate endpoints versus outcomes, and the cost of health care.
George A
GA
Beller
D000328:Adult; D003324:Coronary Artery Disease / Q000150:complications / Q000000981:diagnostic imaging* / Q000191:economics; D005260:Female; D017048:Health Care Costs; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000191:economics / Q000379:methods*; D019275:Radiopharmaceuticals / Q000191:economics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D012984:Software; D012986:Software Validation; D017256:Technetium Tc 99m Sestamibi / Q000191:economics; D013673:Technology Assessment, Biomedical; D015899:Tomography, Emission-Computed, Single-Photon / Q000191:economics / Q000379:methods*; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging* / Q000191:economics / Q000209:etiology
D019275:Radiopharmaceuticals; D017256:Technetium Tc 99m Sestamibi